Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Boehringer Ingelheim Pharmaceuticals |
---|---|
Information provided by: | Boehringer Ingelheim Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00122434 |
The primary objective of this study is to determine the optimum dose of BEA 2180 BR inhalation solut ion delivered by the Respimat ? inhaler once daily for four weeks in patients with COPD.
Condition | Intervention | Phase |
---|---|---|
Pulmonary Disease, Chronic Obstructive |
Drug: BEA 2180 BR Drug: tiotropium |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment |
Official Title: | A Randomized, Multiple-Dose, Double-Blind, Placebo- and Active Controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat? Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD) |
Estimated Enrollment: | 378 |
Estimated Study Completion Date: | December 2006 |
Ages Eligible for Study: | 40 Years to 83 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
1. Patients with any other significant disease will be excluded. 2. Patients with a history of asthma or allergic rhinitis will be excluded.
Investigator: | Boehringer Ingelheim Study Coordinator |
Study ID Numbers: | 1205.4 |
Study First Received: | July 18, 2005 |
Last Updated: | January 31, 2008 |
ClinicalTrials.gov Identifier: | NCT00122434 |
Health Authority: | Unspecified |
Signs and Symptoms Lung Diseases, Obstructive Respiratory Tract Diseases Lung Diseases |
Respiration Disorders Chronic Disease Tiotropium Pulmonary Disease, Chronic Obstructive |
Respiratory System Agents Parasympatholytics Disease Attributes Neurotransmitter Agents Cholinergic Antagonists Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Asthmatic Agents |
Cholinergic Agents Pharmacologic Actions Pathologic Processes Autonomic Agents Therapeutic Uses Peripheral Nervous System Agents Bronchodilator Agents |